Abstract
Objectives: Hypertrophic scar (HS) results from burns or trauma, causing aesthetic and functional issues. However, observational studies have linked inflammatory cytokines to HS, but the causal pathways involved are unclear. We aimed to determine how circulating inflammatory cytokines contribute to HS formation.
Methods:
Two-sample Mendelian randomization (MR) was used to identify genetic variants associated with hypertrophic scar in a comprehensive, publicly available genome-wide association study (GWAS) involving 766 patients and 207,482 controls of European descent. Additionally, data on 91 plasma proteins were drawn from a GWAS summary involving 14,824 healthy participants. Causal relationships between exposures and outcomes were investigated primarily using the inverse variance weighted (IVW) method. Furthermore, a suite of sensitivity analyses, including MR‒Egger and weighted median approaches, were concurrently employed to fortify the robustness of the conclusive findings. Finally, reverse MR analysis was conducted to evaluate the plausibility of reverse causation between hypertrophic scar and the cytokines identified in our study.
Results: In inflammatory cytokines, there was evidence of inverse associations of osteoprotegerin(OPG) levels(OR = 0.59, 95% CI =0.41~0.85, p=0.01), and leukemia inhibitory factor(LIF) levels(OR = 0.51, 95% CI =0.32~0.82, p=0.01) are a nominally negative association with hypertrophic scar risk, while CUBdomain-domain-containing protein 1(CDCP1) level(OR = 0.59, 95% CI =0.41~0.85, p=0.01) glial cell line-derived neurotrophic factor(GDNF) levels(OR = 1.42, 95% CI =1.03~1.96, p=0.01) and programmed cell death 1 ligand 1(PD-L1) levels(OR = 1.47, 95% CI =1.92~2.11, p=0.04) showed a positive association with hypertrophic scar risk. These associations were similar in the sensitivity analyses.
Conclusions: According to our MR findings, OPG and LIF have a protective effect on hypertrophic scar, while CDCP1, GDNF, and PD-L1 have a risk-increasing effect on Hypertrophic scar. Our study adds to the current knowledge on the role of specific inflammatory biomarker pathways in hypertrophic scar. Further validation is needed to assess the potential of these cytokines as pharmacological or lifestyle targets for hypertrophic scar prevention and treatment.